Welcome to the THRIVE Study

The THRIVE study (also known as HPS2-THRIVE) is an international clinical trial run by the University of Oxford's Clinical Trial Service Unit (CTSU). We want to find out if raising good HDL cholesterol (using a drug called ER niacin/laropiprant) will help to prevent heart attacks and stroke.

Who is taking part in THRIVE?

• THRIVE will involve a total of 25,000 men and women
• About 8,500 participants will be from the UK
• Elsewhere, about 10,500 participants will be from China and 6,000 from Scandinavia
• There are over 240 hospitals and clinics currently involved in the study

As of December 2009 we have recruited over 23,000 people into the THRIVE study. Over 6,000 of these are from the UK.

Who is this website for?

• Participants already in the THRIVE study
• People with circulatory problems who have been invited to take part in the study
• Invitees' doctors and other healthcare professionals

For further information about the study click on the links in the menu bars above and to the left.

This website was last updated on 18th December 2009